ANA 12

Key Product Details

Product Description

ANA 12 is a TrkB receptor antagonist. Demonstrates a 2-site mode of action, preventing activation by BDNF non-competitively (IC₅₀ values are 45.6 nM and 41.1 μM for the high and low affinity sites respectively). Displays no effect on TrkA and TrkC in an assay of neurite outgrowth. Demonstrates antidepressant properties. Also exhibits anti-seizure effects in an ischemia-induced neonatal seizure model by blocking down-regulation of KCC2.

Product Specifications for ANA 12

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for ANA 12

The following data is based on the product molecular weight 407.49.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

4 3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	12.27 mL	61.35 mL	122.70 mL
1 mM	2.45 mL	12.27 mL	24.54 mL
2 mM	1.23 mL	6.14 mL	12.27 mL
10 mM	0.25 mL	1.23 mL	2.45 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 69 publications citing the usage of this product.

• Carter Dose-dependent reversal of KCC2 hypofunction and phenobarbital-resistant neonatal seizures by ANA12. Sci.Rep. 2018 PMID: 30097625
• Cazorla Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J.Clin.Invest. 2011 PMID: 21505263

Product Documents for ANA 12